{"id":1242,"date":"2026-11-02T08:58:21","date_gmt":"2026-11-02T06:58:21","guid":{"rendered":"https:\/\/www.pqra.gr\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/"},"modified":"2026-11-02T09:01:51","modified_gmt":"2026-11-02T07:01:51","slug":"orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four","status":"publish","type":"post","link":"https:\/\/www.pqra.gr\/el\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/","title":{"rendered":"Orphan Exclusivity in the Reformed EU Framework: Nine Years, Eleven Years or Four"},"content":{"rendered":"<p style=\"font-size:19px;line-height:1.7;color:#33414d;\"><strong>The reform of EU pharmaceutical law reshapes market exclusivity for orphan medicines. Published analyses of the final compromise describe a modulated system in place of the current uniform period.<\/strong><\/p>\n<h2>The reported periods<\/h2>\n<p>Law firm summaries report a standard orphan market exclusivity of nine years, an extended period of eleven years for breakthrough products where no EU-authorised medicine exists for the condition and the product offers a clinically relevant reduction in morbidity or mortality, and a shorter period of four years for products relying on the well-established use pathway.<\/p>\n<h2>A change of architecture<\/h2>\n<p>The new Regulation repeals Regulation (EC) No 141\/2000, so orphan rules are absorbed into the general framework. Reporting indicates that new exclusivity periods apply to orphan products whose applications are submitted after the Regulation applies, which is expected around late 2028. An EMA register for orphan medicines is also foreseen.<\/p>\n<h2>Why the distinction matters<\/h2>\n<ul><li><strong>Valuation.<\/strong> Modulated exclusivity changes the revenue horizon for rare disease assets.<\/li><li><strong>Evidence strategy.<\/strong> Demonstrating a clinically relevant benefit over existing options becomes more valuable.<\/li><li><strong>Competition.<\/strong> Existing orphan products retain their current protection, while new entrants face different expectations.<\/li><\/ul>\n<h2>Interaction with market access<\/h2>\n<p>Longer exclusivity does not guarantee reimbursement. For rare diseases, joint clinical assessment will apply to orphan medicines from 2028 under the HTA Regulation, so regulatory and HTA planning for such products should be integrated.<\/p>\n<h2>How PQRA helps<\/h2>\n<p>PQRA supports rare disease sponsors with designation and maintenance strategy, protocol assistance planning, and the integration of regulatory timelines with HTA and Greek access preparation.<\/p>\n<p><strong><a href=\"\/el\/contact\/\">Contact PQRA to discuss your situation<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>The reform of EU pharmaceutical law reshapes market exclusivity for orphan medicines. Published analyses of the final compromise describe a modulated system in place of the current uniform period. The reported periods Law firm summaries report a standard orphan market exclusivity of nine years, an extended period of eleven years for breakthrough products where no [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1273,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"saved_in_kubio":false,"_swpsp_post_exclude":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1242","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Orphan Exclusivity in the Reformed EU Framework: Nine Years, Eleven Years or Four - PQRA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pqra.gr\/el\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/\" \/>\n<meta property=\"og:locale\" content=\"el_GR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Orphan Exclusivity in the Reformed EU Framework: Nine Years, Eleven Years or Four - PQRA\" \/>\n<meta property=\"og:description\" content=\"The reform of EU pharmaceutical law reshapes market exclusivity for orphan medicines. Published analyses of the final compromise describe a modulated system in place of the current uniform period. The reported periods Law firm summaries report a standard orphan market exclusivity of nine years, an extended period of eleven years for breakthrough products where no [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pqra.gr\/el\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/\" \/>\n<meta property=\"og:site_name\" content=\"PQRA\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-02T06:58:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-02T07:01:51+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u03bb\u03b5\u03c0\u03c4\u03cc\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\"},\"headline\":\"Orphan Exclusivity in the Reformed EU Framework: Nine Years, Eleven Years or Four\",\"datePublished\":\"2026-11-02T06:58:21+00:00\",\"dateModified\":\"2026-11-02T07:01:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\\\/\"},\"wordCount\":266,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-cover-12.png\",\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\\\/\",\"name\":\"Orphan Exclusivity in the Reformed EU Framework: Nine Years, Eleven Years or Four - PQRA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-cover-12.png\",\"datePublished\":\"2026-11-02T06:58:21+00:00\",\"dateModified\":\"2026-11-02T07:01:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\\\/#breadcrumb\"},\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-cover-12.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-cover-12.png\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pqra.gr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Orphan Exclusivity in the Reformed EU Framework: Nine Years, Eleven Years or Four\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"name\":\"PQRA\",\"description\":\"Your trusted partner in Pharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pqra.gr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"el\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\",\"name\":\"PQRA\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"width\":594,\"height\":362,\"caption\":\"PQRA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/www.pqra.gr\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Orphan Exclusivity in the Reformed EU Framework: Nine Years, Eleven Years or Four - PQRA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pqra.gr\/el\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/","og_locale":"el_GR","og_type":"article","og_title":"Orphan Exclusivity in the Reformed EU Framework: Nine Years, Eleven Years or Four - PQRA","og_description":"The reform of EU pharmaceutical law reshapes market exclusivity for orphan medicines. Published analyses of the final compromise describe a modulated system in place of the current uniform period. The reported periods Law firm summaries report a standard orphan market exclusivity of nine years, an extended period of eleven years for breakthrough products where no [&hellip;]","og_url":"https:\/\/www.pqra.gr\/el\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/","og_site_name":"PQRA","article_published_time":"2026-11-02T06:58:21+00:00","article_modified_time":"2026-11-02T07:01:51+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc":"admin","\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2":"1 \u03bb\u03b5\u03c0\u03c4\u03cc"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pqra.gr\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/#article","isPartOf":{"@id":"https:\/\/www.pqra.gr\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/"},"author":{"name":"admin","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c"},"headline":"Orphan Exclusivity in the Reformed EU Framework: Nine Years, Eleven Years or Four","datePublished":"2026-11-02T06:58:21+00:00","dateModified":"2026-11-02T07:01:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pqra.gr\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/"},"wordCount":266,"commentCount":0,"publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"image":{"@id":"https:\/\/www.pqra.gr\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-cover-12.png","articleSection":["Uncategorized"],"inLanguage":"el","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.pqra.gr\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.pqra.gr\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/","url":"https:\/\/www.pqra.gr\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/","name":"Orphan Exclusivity in the Reformed EU Framework: Nine Years, Eleven Years or Four - PQRA","isPartOf":{"@id":"https:\/\/www.pqra.gr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pqra.gr\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/#primaryimage"},"image":{"@id":"https:\/\/www.pqra.gr\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-cover-12.png","datePublished":"2026-11-02T06:58:21+00:00","dateModified":"2026-11-02T07:01:51+00:00","breadcrumb":{"@id":"https:\/\/www.pqra.gr\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/#breadcrumb"},"inLanguage":"el","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pqra.gr\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/"]}]},{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/#primaryimage","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-cover-12.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-cover-12.png","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.pqra.gr\/orphan-exclusivity-in-the-reformed-eu-framework-nine-years-eleven-years-or-four\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pqra.gr\/"},{"@type":"ListItem","position":2,"name":"Orphan Exclusivity in the Reformed EU Framework: Nine Years, Eleven Years or Four"}]},{"@type":"WebSite","@id":"https:\/\/www.pqra.gr\/#website","url":"https:\/\/www.pqra.gr\/","name":"PQRA","description":"Your trusted partner in Pharma","publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pqra.gr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"el"},{"@type":"Organization","@id":"https:\/\/www.pqra.gr\/#organization","name":"PQRA","url":"https:\/\/www.pqra.gr\/","logo":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","width":594,"height":362,"caption":"PQRA"},"image":{"@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c","name":"admin","image":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/www.pqra.gr"]}]}},"_links":{"self":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/comments?post=1242"}],"version-history":[{"count":1,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1242\/revisions"}],"predecessor-version":[{"id":1274,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1242\/revisions\/1274"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media\/1273"}],"wp:attachment":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media?parent=1242"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/categories?post=1242"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/tags?post=1242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}